Technology that provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes. The method is convenient, easy-to-use, and validated. It measures tissue accumulation of Advanced Glycation End products (AGEs) by means of fluorescence techniques. AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes and cardiovascular disease.
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of DiagnOptics plus 4810 other startups.
